We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

230 hedge funds and large institutions have $561M invested in Nektar Therapeutics in 2022 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 70 increasing their positions, 74 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

814% more call options, than puts

Call options by funds: $2M | Put options by funds: $219K

20% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 25

1% more funds holding

Funds holding: 227 → 230 (+3)

0.3% less ownership

Funds ownership: 6.53% → 6.24% (-0.3%)

5% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 74

19% less capital invested

Capital invested by funds: $693M → $561M (-$131M)

Holders
230
Holders Change
+3
Holders Change %
+1.32%
% of All Funds
3.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
70
Reduced
74
Closed
25
Calls
$2M
Puts
$219K
Net Calls
+$1.78M
Net Calls Change
-$1.41M

Top Buyers

1
BlackRock
BlackRock
New York
+$13.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$10.2M
3
Northern Trust
Northern Trust
Illinois
+$3.87M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.21M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$2.89M

Top Sellers

1
First Trust Advisors
First Trust Advisors
Illinois
-$29.8M
2
MC
Maverick Capital
Texas
-$12.2M
3
GPP
Great Point Partners
Connecticut
-$10.7M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$4.33M
5
State Street
State Street
Massachusetts
-$3.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
226
Corton Capital
Ontario, Canada
– -$58K -1,020 Closed
TLP
227
Tri Locum Partners
New York
– -$51K -893 Closed
FAIM
228
Financial Advocates Investment Management
Washington
– -$47K -829 Closed
SA
229
Syntax Advisors
New York
– -$41K -712 Closed
VCG
230
Vantage Consulting Group
Virginia
– -$41K -712 Closed
AGM
231
Alpine Global Management
New York
– -$39K -680 Closed
MCIA
232
Mountain Capital Investment Advisors
Colorado
– -$39K -667 Closed
GWS
233
Glassman Wealth Services
Virginia
– -$19.5K -328 -99%
PFBT
234
Parkside Financial Bank & Trust
Missouri
– -$5.41K -91 -90%
LC
235
Lindbrook Capital
California
– -$2.38K -40 -87%
SIAP
236
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
– -$2K -37 Closed
FBC
237
Fairfield, Bush & Co
Connecticut
– -$1K -13 Closed
GWM
238
Geneos Wealth Management
Colorado
– -$714 -12 -41%
C
239
Covestor
United Kingdom
– -$59 -1 -33%
MAM
240
Meeder Asset Management
Ohio
– -$59 -1 -11%
AF
241
Allworth Financial
California
– +$178 +3 New
JWM
242
Janiczek Wealth Management
Colorado
– +$416 +7 New
FMII
243
Farmers & Merchants Investments Inc
Nebraska
– +$476 +8 New
MFA
244
McClarren Financial Advisors
Pennsylvania
– +$595 +10 New
Rockefeller Capital Management
245
Rockefeller Capital Management
New York
– +$595 +10 New
6 7 8 9
10

NKTR Hedge Fund Activity: Q3 2022 in Review

230 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2022, worth a combined $561M — down 19% from $693M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new NKTR positions and 25 closed out — a net gain of 5 holders — while 70 added to existing stakes and 74 trimmed.

The largest buyer was BlackRock, adding an estimated $13.8M. The largest seller was First Trust Advisors, exiting entirely with an estimated $29.8M sold.

  • 230 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2022, up from 227 in Q2 2022.
  • Funds reported $561M of Nektar Therapeutics stock for Q3 2022, down 19% quarter-over-quarter.
  • 30 funds opened new Nektar Therapeutics positions in Q3 2022 and 25 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q3 2022 was BlackRock, an estimated $13.8M added.
  • The largest Nektar Therapeutics seller in Q3 2022 was First Trust Advisors, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2022.